Philip Nadeau

“So, you mentioned Astellas and Veer have noted that 5500 achieved proof of concept. We're curious whether you'd be willing to share any of the criteria for proof of concept or even what categories were analyzed from response to duration to safety, things like that.”

“Question on Ingressa trends and guidance. So if we back out the $20 million that you mentioned of orders this quarter, even taking that out, it does look like the top end of guidance assumes it's sequentially down Q4.”

“We wanted to ask about the upcoming Lidafilamab data in SLE. I think that is now becoming a focus of investors. Can I just discuss its confidence that those Phase 3 trials will succeed and maybe work into that, the differences in the Phase 3 design versus Phase 2?”

“On HDV, you mentioned the human factor study. Can you go into a little bit more detail as to how tovinella are being dosed in the pivotal trials and how you hope to have the commercial formulation dosed in terms of devices as well as at home versus in the clinic.”

“So, first, in NPM1, I apologize if I missed this. Did you say where you estimate your share of NPM new patient starts was this quarter and how that compared to last quarter?”